Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO)
A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients
Sponsor: Fundación GECP
This PHASE2 trial investigates Carcinoma Bronchiogenic Stage III and Carcinoma, Non-Small-Cell Lung and is currently ongoing. Fundación GECP leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Jul 2022 — Jul 2023 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Dec 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fundación GECP
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Badalona, Spain , Barcelona, Spain , Bilbao, Spain , Elche, Spain , Girona, Spain , Jaén, Spain , Las Palmas de Gran Canaria, Spain , Leganés, Spain and 7 more locations